Health
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc vs iv trastuzumab – MD Linx
MDLinx original journal summary on Breast Cancer, Oncology from The Breast
Researchers investigated cardiotoxicity related to subcutaneous (s.c.) vs intravenous (i.v.) trastuzumab treatment of early-stage, HER2-positive breast cancer in a real-world population as well as tried to define its predisposing factors. Data for 363 adult patients managed with adjuvant trastuzumab for HER2-positive breast cancer were analyzed retrospectively. It was found that i.v. administration conferred a higher cardiotoxicity rate vs s.c. formulation, and especially in cases with cardiovascular…
-
Noosa News20 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Noosa News22 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Business7 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General16 hours ago‘Potential’ hacker contacts Qantas over data breach